(Reuters) – Inovio Pharmaceuticals Inc on Tuesday expanded its partnership with Advaccine Biopharmaceuticals to conduct a late-stage trial of its COVID-19 vaccine candidate.
The company said the vaccine, INO-4800, will be tested among those who are 18 years and older across several countries, mainly in Latin America and Asia.
(Reporting by Amruta Khandekar; Editing by Arun Koyyur)
